Charlottesville, Virginia 22908


Purpose:

This study evaluates whether it is safe to administer a helper peptide vaccine with dabrafenib and trametinib. This study will also evaluate the effects of the combination of the peptide vaccine and dabrafenib and trametinib on the immune system. We will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.


Criteria:

Inclusion Criteria: - Participants with measurable stage IIIB, IIIC, or IV melanoma that have clinical or radiological evidence of disease. These participants may have had cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma. Staging must be confirmed by cytological or histological examination. Staging of cutaneous melanoma will be based on the revised AJCC staging system. - Participants must be eligible to be treated with BRAF inhibitor and MEK inhibitor combination. - Participants will be required to have radiological studies to define radiologically evident disease. Required studies include: - Chest CT scan, - Abdominal and pelvic CT scan, and - Head CT scan or MRI - Participants who have metastatic melanoma available for biopsy pretreatment and on day 22 must consent to having those biopsies. These metastases may be in nodes, skin, soft tissue, liver, or other sites that can be accessed by needle biopsy, incisional or excisional biopsy, with or without image guidance. - Participants who have had brain metastases will be eligible if all of the following are true: - The total number of brain metastases ever ≤ 3 - Each brain metastasis must have been completely removed by surgery or each unresected brain metastasis must have been treated with stereotactic radiosurgery. - There has been no evident growth of any brain metastasis since the most recent treatment - No brain metastasis is > 2 cm in diameter at the time of registration - The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed ≥ 1 week and ≤ 6 months prior to registration. - ECOG performance status of 0 or 1 - Participants must have the ability and willingness to give informed consent - Laboratory parameters as follows: - ANC > 1000/mm3 - Platelets > 100,000/mm3 - Hgb > 9 g/dL - HgB-A1c ≤ 7.5% - AST and ALT up to 2.5 x upper limits of normal (ULN). Patients known to have Gilbert's disease may be eligible with AST and ALT up to 5 x ULN. - Bilirubin up to 2.5 x ULN - Alkaline phosphatase up to 2.5 x ULN. - Creatinine up to 1.5 x ULN - Age 18 years or older at registration - Participants must have at least two intact (undissected) axillary and/or inguinal lymph node basins Exclusion Criteria: - Participants who have received the following medications or treatments at any time within 4 weeks of registration: - • Chemotherapy - Interferon (e.g. Intron-A®) - Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥ 1 week and ≤ 6 months prior to registration) - Allergy desensitization injections - Corticosteroids, administered transdermally, parenterally or orally. Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) are not permitted. Topical corticosteroids are acceptable. - Growth factors (e.g. Procrit®, Aranesp®, Neulasta®) - Interleukins (e.g. Proleukin®) - Any investigational medication - Targeted therapies specific for mutated BRAF - MEK inhibitor - HIV positivity or evidence of active Hepatitis C virus. - Participants who are currently receiving nitrosoureas or who have received this therapy 6 weeks prior to registration - Participants who are currently receiving a checkpoint molecule blockade therapy, or who have received this therapy within 3weeks prior to registration. - Participants with known or suspected allergies to any component of the vaccine. - Participants may not have been vaccinated previously with any of the synthetic peptides included in this protocol. Participants who have received vaccinations containing agents other than the synthetic peptides included in this protocol and have recurred during or after administration of the vaccine will be eligible to enroll 12 weeks following their last vaccination. - Pregnancy. - Female participants must not be breastfeeding - Participants in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol in the opinion of the investigator. - Participants classified according to the New York Heart Association classification as having Class III or IV heart disease. - Participants with uncontrolled diabetes, defined as having a HgB-A1c greater than 7.5%. - Participants must not have had prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement. Participants with an active autoimmune disorder requiring these therapies are also excluded. - Participants who have another cancer diagnosis, except that the following diagnoses will be allowed: - squamous cell cancer of the skin without known metastasis - basal cell cancer of the skin without known metastasis - carcinoma in situ of the breast (DCIS or LCIS) - carcinoma in situ of the cervix - any cancer without distant metastasis that has been treated successfully, without evidence of recurrence or metastasis for over 3 years - Participants with known addiction to alcohol or drugs who are actively taking those agents, or participants with recent (within 1 year of registration) or ongoing illicit IV drug use. - Body weight < 110 pounds - Participants with a known history of glucose-6-phosphate dehydrogenase deficiency.


NCT ID:

NCT02382549


Primary Contact:

Principal Investigator
Elizabeth Gaughan, MD
University of Virginia

Alexandra Carney, MPH
Phone: 434-982-6714
Email: ALC6A@virginia.edu


Backup Contact:

Email: EH4M@virginia.edu
Emily Allred, PhD
Phone: 434-982-1902


Location Contact:

Charlottesville, Virginia 22908
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.